全文获取类型
收费全文 | 427篇 |
免费 | 42篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 9篇 |
妇产科学 | 4篇 |
基础医学 | 73篇 |
口腔科学 | 8篇 |
临床医学 | 47篇 |
内科学 | 154篇 |
皮肤病学 | 5篇 |
神经病学 | 31篇 |
特种医学 | 7篇 |
外科学 | 33篇 |
综合类 | 1篇 |
一般理论 | 1篇 |
预防医学 | 24篇 |
眼科学 | 7篇 |
药学 | 56篇 |
肿瘤学 | 8篇 |
出版年
2023年 | 1篇 |
2022年 | 3篇 |
2021年 | 12篇 |
2020年 | 11篇 |
2019年 | 22篇 |
2018年 | 30篇 |
2017年 | 7篇 |
2016年 | 11篇 |
2015年 | 20篇 |
2014年 | 8篇 |
2013年 | 20篇 |
2012年 | 27篇 |
2011年 | 31篇 |
2010年 | 22篇 |
2009年 | 18篇 |
2008年 | 29篇 |
2007年 | 27篇 |
2006年 | 26篇 |
2005年 | 24篇 |
2004年 | 14篇 |
2003年 | 18篇 |
2002年 | 9篇 |
2001年 | 9篇 |
2000年 | 9篇 |
1999年 | 4篇 |
1998年 | 1篇 |
1995年 | 3篇 |
1994年 | 3篇 |
1993年 | 2篇 |
1992年 | 4篇 |
1991年 | 4篇 |
1990年 | 1篇 |
1989年 | 3篇 |
1987年 | 5篇 |
1985年 | 3篇 |
1984年 | 3篇 |
1983年 | 3篇 |
1981年 | 4篇 |
1979年 | 1篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1976年 | 2篇 |
1975年 | 4篇 |
1974年 | 1篇 |
1973年 | 2篇 |
1972年 | 1篇 |
1969年 | 2篇 |
1967年 | 1篇 |
排序方式: 共有469条查询结果,搜索用时 15 毫秒
1.
Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips 下载免费PDF全文
Morosini MI García-Castillo M Loza E Pérez-Vázquez M Baquero F Cantón R 《Journal of clinical microbiology》2005,43(9):4480-4485
Inhaled administration of tobramycin assures high concentrations in cystic fibrotic lungs, improving the therapeutic ratio over that of parenteral tobramycin levels, particularly against Pseudomonas aeruginosa. Conventional Clinical and Laboratory Standards Institute (CLSI; formerly National Committee for Clinical Laboratory Standards) breakpoints only consider parenteral levels and do not take into account these high antimicrobial concentrations. The Spanish Antibiogram Committee (The MENSURA Group) has tentatively defined specific breakpoint values for inhaled tobramycin when testing P. aeruginosa isolates from cystic fibrosis (CF) patients (susceptible, < or =64 microg/ml; resistant, > or =128 microg/ml). The antimicrobial susceptibilities of 206 prospectively collected CF P. aeruginosa isolates were determined by the reference agar dilution method. For tobramycin, the performance of high range tobramycin Etest strips (AB Biodisk, Solna, Sweden) and conventional tobramycin disks were assessed with the same collection. Applying MENSURA proposed breakpoints, 95.1% of the strains were categorized as susceptible to tobramycin, either using agar dilution or Etest high-range strips (99% categorical agreement between both methods). With CLSI breakpoints, susceptibility rates decreased to 79.1 and 81.1% for agar dilution and Etest strips, respectively (83.5% categorical agreement). Minor, major, and very major errors for Etest strips (CLSI criteria) were 13.6, 1.2, and 14.8%, respectively. Upon applying the new proposed criteria for inhaled tobramycin, only one major and one very major error were observed with Etest strips. Whenever inhaled tobramycin is considered for therapy, we suggest that P. aeruginosa strains from CF patients categorized as intermediate or resistant to tobramycin according to the CLSI criteria should be retested with high-range Etest strips and recategorized using MENSURA interpretive criteria. CLSI breakpoints should still be followed when intravenous tobramycin is used in CF patients, particularly during the course of exacerbations. 相似文献
2.
3.
Vega Jovani Estíbaliz Loza M. Jesús García de Yébenes Miguel Ángel Descalzo Juan Manuel Barrio Loreto Carmona César Hernández-García 《Reumatología clinica》2012,8(3):114-119
ObjectiveOur objective was to describe the variability in the management of spondyloarthritis (SA) in Spain in terms of healthcare resources and their use.MethodsA review of 1168 medical files of patients seen in randomly selected Spanish hospital rheumatology departments. We analyzed demographic variables and variables related to the consumption of health resources.ResultsThe total number of visits to rheumatology were 5,908 with a rate of 254 visits/100 patient-years. The total number of visits to rheumatology specialty nurses was 775, with a rate of 39 visits/100 patient-years, and there were 446 hospitalizations, representing a rate of 22 per 100 patient-years. The number of admissions due to SA was 89, with a rate of 18 admissions/100 patient-years. Total visits to other specialists was 4,307 with a rate of 200/100 patient-years. The total number of orthopedic surgeries was 41, which leads to a rate of 1.8 surgeries/100 patient-years.ConclusionsThe data regarding visits to the rheumatologist and prosthetic surgery of patients with in Spain is similar to most studies published in our environment, however, other aspects concerning the use of health resources are different compared to other countries. This data may help to understand and improve organizational aspects of management of SA in Spanish hospitals. 相似文献
4.
5.
6.
Nazanin Zounemat Kermani Mansoor Saqi Paul Agapow Stelios Pavlidis Chihhsi Kuo Kai Sen Tan Sharon Mumby Kai Sun Matthew Loza Frederic Baribaud Ana R. Sousa John Riley Asa M. Wheelock Craig E. Wheelock Bertrand De Meulder Jim Schofield Stephany Sánchez-Ovando Jodie Louise Simpson Katherine Joanne Baines Peter A. Wark Charles Auffray Sven-Erik Dahlen Peter J. Sterk Ratko Djukanovic Ian M. Adcock Yi-ke Guo Kian Fan Chung U-BIOPRED Project Team 《Allergy》2021,76(1):380-383
7.
8.
9.
10.
Terrier B Krastinova E Marie I Launay D Lacraz A Belenotti P de Saint-Martin L Quemeneur T Huart A Bonnet F Le Guenno G Kahn JE Hinschberger O Rullier P Diot E Lazaro E Bridoux F Zénone T Carrat F Hermine O Léger JM Mariette X Senet P Plaisier E Cacoub P 《Blood》2012,119(25):5996-6004
Data on the clinical spectrum and therapeutic management of noninfectious mixed cryoglobulinemia vasculitis (CryoVas) in the era of hepatitis C virus screening are lacking. We analyzed data from 242 patients with noninfectious mixed CryoVas included in the French multicenter CryoVas survey. Baseline manifestations were purpura (75%), peripheral neuropathy (52%), arthralgia or arthritis (44%), glomerulonephritis (35%), cutaneous ulcers (16%), and cutaneous necrosis (14%). A connective tissue disease was diagnosed in 30% and B-cell non-Hodgkin lymphoma in 22%, whereas the CryoVas was considered to be essential in 48%. With the use of Cox-marginal structural models, rituximab plus corticosteroids showed the greater therapeutic efficacy compared with corticosteroids alone and alkylating agents plus corticosteroids to achieve complete clinical, renal, and immunologic responses and a prednisone dosage < 10 mg/d at 6 months. However, this regimen was also associated with severe infections, particularly when high doses of corticosteroids were used, whereas death rates did not differ between the therapeutic regimens. The role of each of these strategies remains to be defined in well-designed randomized controlled trials. 相似文献